(Bloomberg) -- DNA-testing company 23andMe Inc. has launched a new tool that aims to predict an infected person’s risk of developing a severe case of Covid-19, expanding the company’s bid to deliver actionable insight on health. An algorithm was created from the data that the company says can predict the likelihood of hospitalization for those infected. “We’ve found giving people actionable information - like this tool - drives meaningful results.”Anyone can use the tool. When the pandemic hit, 23andMe sought to demonstrate the value of genomics and a more personalized health care approach. Blood-Type ResearchIn June, 23andMe published research that bolstered evidence that a person’s blood type can affect a person’s susceptibility to Covid-19 by looking at a gene that influences blood type.
